A suspect is escorted by police officers at Kilimani Police Station after he was found operating a pharmacy without a licence in Nairobi's Kawangware on Oct 5, 2021. [File, Standard]
Health Ministry warns against sale of drugs standardised in India
Health & Science
By
Maryann Muganda
| Jan 19, 2025
The Ministry of Health, through the Pharmacy and Poisons Board (PPB), has warned against the importation and sale of unregistered health products in Kenya, particularly those referencing the Indian Pharmacopoeia (IP).
In a statement released on Friday, the board’s Chief Executive Officer, Fred Siyoi, highlighted growing concerns over the influx of such products into the local market.
The Indian Pharmacopoeia, a set of standards used to regulate drugs in India, sets quality, safety, and efficacy requirements for medicines sold within the country.
However, according to the PPB, these standards are not applicable in Kenya.
READ MORE
Trump imposes 10pc tariffs on Kenyan goods
Lack of written tenant-landlord agreements hampers tax collection
New architects lobby president spells out agenda
Edible oil processors rekindle push to scrap import duty tax
Geothermal still tops Kenya's energy mix despite output decline
Sudan tea export ban threatens nascent value addition hub in Mombasa
Practitioners bear burden of restoring trust in property sector
IM Bank opens new branch in Bungoma
Kenyan coffee prices surge as NCE records Sh19.3billion in sales
Coffee factories earn Sh19.3 billion from 375,843 bags at NCE
Siyoi emphasised that products citing the Indian Pharmacopoeia do not meet Kenyan registration requirements and therefore cannot be legally sold, imported, or distributed in the country.
“The Indian Pharmacopoeia is not within the purview of drug registration requirements in the country, and as such, products citing this standard are not compliant with Kenyan regulations,” said Siyoi.
He further warned pharmaceutical stakeholders—including manufacturers, distributors, and retailers—to refrain from handling or trading in such unregistered products.
Siyoi’s statement reiterated that all pharmaceutical products sold or distributed in Kenya must be approved by the Pharmacy and Poisons Board in compliance with the Pharmacy and Poisons Act and other relevant regulations.
The board also underscored that failure to adhere to these directives would result in significant penalties, including the seizure of unregistered products, revocation of licenses, and legal prosecution.
“Failure to comply with this directive will attract severe regulatory actions, including but not limited to seizure of products, revocation of licenses, and prosecution as stipulated under the law,” warned Siyoi.
He also urged medical professionals to be cautious and ensure that any pharmaceutical products they handle are properly registered with the PPB.
The board also emphasised that products that are not duly registered by the PPB are strictly prohibited from entering the market.
Share this story